2-(4-氨基-2-氯-5-甲基苯基)-2-(4-氯苯基)乙腈 | 61437-85-2

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氨基-2-氯-5-甲基苯基)-2-(4-氯苯基)乙腈
• 中文别名: 4-氨基-2-氯-α-(4-氯苯基)-5-甲基苯乙腈；4-氨基-2-氯-alpha-(4-氯苯基)-5-甲基苯乙腈；4-氨基-2-氯-alfa-(4-氯苯基)-5-甲基苯乙腈；2-(4-氨基-2-氯-5-甲基苯基)-2-(4-氯苯基)乙氰；Closantel氨基化合物
• 英文名称: 2-(4-amino-2-chloro-5-methylphenyl)-2-(4-chlorophenyl)acetonitrile
• 英文别名: 4-amino-2-chloro-α-(4-chlorophenyl)-5-methylbenzeneacetonitrile；4-Amino-2-chloro-α-4-chlorophenyl-5-methylphenyl-acetonitrile
• CAS: 61437-85-2
• 化学式: C₁₅H₁₂Cl₂N₂
• mdl: MFCD00044794
• 分子量: 291.18
• InChiKey: SCNVPMWFNDBBQS-UHFFFAOYSA-N

物化性质

• 熔点：
  150.5°C
• 沸点：
  444.03°C (rough estimate)
• 密度：
  1.2635 (rough estimate)
• LogP：
  4.12

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2926909090

SDS

Name:	4-Amino-2-chloro-alpha-(4-chlorophenyl)-5- methylbenzeneacetonitrile Material Safety Data Sheet
Synonym:	None
CAS:	61437-85-2

Section 1 - Chemical Product MSDS Name:4-Amino-2-chloro-alpha-(4-chlorophenyl)-5- methylbenzeneacetonitrile Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
61437-85-2	4-Amino-2-chloro-alpha-(4-chlorophenyl	97%	262-792-6

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
Harmful if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Call a poison control center. If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Wash hands before eating. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with skin and eyes. Do not ingest or inhale.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate general or local explosion-proof ventilation to keep airborne levels to acceptable levels.
Exposure Limits CAS# 61437-85-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 147 - 153 deg C
Autoignition Temperature: Not available.
Flash Point: 570 deg C ( 1,058.00 deg F)
Explosion Limits, lower: 15.00 vol %
Explosion Limits, upper: .00 vol %
Decomposition Temperature:
Solubility in water: 20 MG/L (20C)
Specific Gravity/Density:
Molecular Formula: C15H12Cl2N2
Molecular Weight: 291.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 61437-85-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Amino-2-chloro-alpha-(4-chlorophenyl)-5-methylbenzeneacetonitrile, 97% (TLC) - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 61437-85-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 61437-85-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 61437-85-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-氨基-2-氯-5-甲基苯基)-2-(4-氯苯基)乙腈 在 镍 盐酸 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 5.0 ℃ 、344.73 kPa 条件下， 反应 61.0h， 生成 N-tert-butoxycarbonyl-2-(4-chlorophenyl)-2-(2-chloro-4-amino-5-methylphenyl)ethylamine
  参考文献：
  名称：

  取代水杨酰苯胺作为细菌中两组分调节系统的抑制剂。

  摘要：

  基于水杨酰苯胺的筛选命中氯梭菌（1）和四氯水杨酰苯胺（9），发现了一种新型的细菌两组分调节系统（TCS）抑制剂。系统的SAR研究与模型TCS KinA / Spo0F相比，证明了水杨酰环中吸引电子的取代基和苯胺部分中的疏水基团具有最佳活性的重要性。另外，含有2，3-二羟基苯甲腈结构基序的衍生物8和16是KinA激酶自磷酸化的有效抑制剂，IC50分别为2.8和6. 3 µM。化合物8还以低于抑制生长的浓度抑制了基因工程化粪肠球菌细胞系中介导万古霉素抗性的TCS（VanS / VanR）。氯沙坦（1），四氯水杨基苯胺（9），

  DOI：

  10.1021/jm9803572
• 作为产物：
  描述：

  对氯苯乙腈 在 甲醇 、 sodium methylate 、 一水合肼 、 sodium hydroxide 作用下， 以 二乙二醇 为溶剂， 反应 9.0h， 生成 2-(4-氨基-2-氯-5-甲基苯基)-2-(4-氯苯基)乙腈
  参考文献：
  名称：

  氯氰碘柳胺钠的制备方法

  摘要：

  本发明公开了一种氯氰碘柳胺钠的制备方法，属于化学药物中间体制备方法技术领域，利用对氯苯乙腈、邻硝基对氯甲苯和2‑羟基‑3,5‑二碘苯甲酸为原料，经缩合反应、还原反应和再缩合反应，然后在氢氧化钠溶液中成盐制备2‑(三氟甲基)吡啶‑3‑甲醛。本发明方法，采用相对友好的还原剂替代铁粉等避免了铁泥和废水等污染物的排放，且简化了后处理，改进后的工艺操作安全简便，反应条件温和，产品收率较高，“三废”少，具有较高的工业化价值。

  公开号：

  CN109851526A

文献信息

• Chemical uncouplers for the treatment of obesity
  申请人：——

  公开号：US20040138301A1

  公开（公告）日：2004-07-15

  This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related diseases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.

  这项发明涉及一种化学解偶联剂，它具有更宽的安全窗口，使其在治疗肥胖症以及因此引发的相关疾病和状况，如动脉硬化、高血压、糖尿病（尤其是2型糖尿病（非胰岛素依赖型糖尿病））、葡萄糖耐量受损、血脂异常、冠心病、胆结石病、骨关节炎以及子宫内膜、乳房、前列腺和结肠等各种癌症以及过早死亡的风险等方面更具吸引力。此外，还包括其他通过增加线粒体呼吸得到改善的条件、疾病和紊乱。
• Antiparasitic salicylanilide derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04005218A1

  公开（公告）日：1977-01-25

  Compounds of the class of salicylanilides substituted in the 4-position of the anilino moiety with a --CH(CN)-Ar group wherein Ar is phenyl, substituted phenyl, thienyl, halothienyl or naphthalenyl, said salicylanilides being useful as parasiticides.

  4-位被--CH(CN)-Ar基团取代的沙利西胺类化合物，其中Ar为苯基、取代苯基、噻吩基、卤代噻吩基或萘基，此类沙利西胺化合物可用作杀虫剂。
• Synthesis of C C, C N coupled novel substituted dibutyl benzothiazepinone derivatives and evaluation of their thrombin inhibitory activity
  作者：C.P. Baburajeev、Chakrabhavi Dhananjaya Mohan、Vijay Pandey、Shobith Rangappa、Naveen Shivalingegowda、Leen Kalash、Sannaningaiah Devaraja、Andreas Bender、Peter E. Lobie、Kanchugarakoppal S. Rangappa、Basappa

  DOI：10.1016/j.bioorg.2019.03.004

  日期：2019.6

  docking studies suggested that the benzothiazepinones evaluated here consistently display hydrogen bonding with Ser214 of thrombin, which is similar to that of the co-crystallized ligand (1-(2R)-2-amino-3-phenyl-propanoyl-N-(2,5dichlorophenyl)methylpyrrolidine-2-carboxamide). DCT displayed additional hydrogen bonding to Ser195 and π-π interactions between its methoxyphenyl groups and Trp60, thereby providing

  血栓的形成是血栓栓塞性疾病的关键事件，在受累患者中会导致较高的死亡率和发病率。在本研究中，我们合成了一个新颖的取代3,3-二丁基-8-甲氧基-2,3-二氢苯并[b] [1,4]噻嗪酮-4（5H）-one衍生物的文库，并对其血小板进行了测试聚集和凝血酶抑制活性。在测试的化合物中，3,3-二丁基-7-（2-氯苯基）-8-甲氧基-2,3-二氢苯并[b] [1,4]噻嗪-4-4（5H）-one（DCT）显示最大IC 50抑制凝血酶值3.85μM，因此选择DCT进行进一步研究。接下来，使用激动剂诱导的血小板聚集模型评估DCT对原发止血的作用。铅化合物以剂量依赖的方式抑制胶原蛋白或ADP或凝血酶诱导的血小板凝集。此外，在评估血浆重新钙化时间（5 µg DCT时为320±11秒），激活部分凝血活酶时间（2 µg时为58.0±0.01秒）和凝血酶原时间（14.7±0.01秒）时，DCT延长了血块形成过程。
• 2-（4-氨基-2-氯-5-甲基苯基）-2-（4-氯苯基） 乙腈的制备方法
  申请人：常州齐晖药业有限公司

  公开号：CN104710328B

  公开（公告）日：2017-02-22

  本发明涉及2‐(4‐氨基‐2‐氯‐5‐甲基苯基)‐2‐(4‐氯苯基)乙腈的制备方法，主要以4‐氯‐α‐[2‐氯‐4‐羟亚氨基‐5‐甲基‐2,5‐亚环己二烯基]苯乙腈经过加氢反应，制备2‐(4‐氨基‐2‐氯‐5‐甲基苯基)‐2‐(4‐氯苯基)乙腈。本发明所述方法具有以下优点：还原采用催化加氢法，污染少，催化剂可以重复利用，降低生产成本。
• Repositioning of an existing drug for the neglected tropical disease Onchocerciasis
  作者：Christian Gloeckner、Amanda L. Garner、Fana Mersha、Yelena Oksov、Nancy Tricoche、Lisa M. Eubanks、Sara Lustigman、Gunnar F. Kaufmann、Kim D. Janda

  DOI：10.1073/pnas.0915125107

  日期：2010.2.23

  Onchocerciasis, or river blindness, is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus that affects more than 37 million people, mainly in third world countries. Currently, the only approved drug available for mass treatment is ivermectin, however, drug resistance is beginning to emerge, thus, new therapeutic targets and agents are desperately needed to treat and cure this devastating disease. Chitin metabolism plays a central role in invertebrate biology due to the critical structural function of chitin for the organism. Taken together with its absence in mammals, targeting chitin is an appealing therapeutic avenue. Importantly, the chitinase OvCHT1 from O. volvulus was recently discovered, however, its exact role in the worm’s metabolism remains unknown. A screening effort against OvCHT1 was conducted using the Johns Hopkins Clinical Compound Library that contains over 1,500 existing drugs. Closantel, a veterinary anthelmintic with known proton ionophore activities, was identified as a potent and specific inhibitor of filarial chitinases, an activity not previously reported for this compound. Notably, closantel was found also to completely inhibit molting of O. volvulus infective L3 stage larvae. Closantel appears to target two important biochemical processes essential to filarial parasites. To begin to unravel closantel’s effects, a retro-fragment-based study was used to define structural elements critical for closantel’s chitinase inhibitor function. As resources towards the development of new agents that target neglected tropical diseases are scant, the finding of an existing drug with impact against O. volvulus provides promise in the hunt for new therapies against river blindness.

  河盲症是一种由丝虫寄生虫Onchocerca volvulus引起的热带病，主要影响第三世界国家的超过3700万人。目前，唯一获批用于大规模治疗的药物是伊维菌素，但药物耐药性开始出现，因此迫切需要新的治疗靶点和药物来治疗和治愈这种毁灭性的疾病。由于几丁质对生物体的关键结构功能，因此几丁质代谢在无脊椎动物生物学中起着核心作用。结合哺乳动物中的缺失，靶向几丁质是一种吸引人的治疗途径。重要的是，最近发现了来自O. volvulus的几丁质酶OvCHT1，但其在虫体代谢中的确切作用尚不清楚。使用约翰霍普金斯临床化合物库进行了针对OvCHT1的筛选工作，该库包含超过1500种现有药物。发现克罗山特尔是一种具有已知质子离子载体活性的兽医驱虫药，是一种有效且特异性的丝虫几丁质酶抑制剂，这种活性以前从未报道过。值得注意的是，发现克罗山特尔还完全抑制了O. volvulus感染性L3期幼虫的蜕皮。克罗山特尔似乎靶向了丝虫寄生虫所必需的两个重要生化过程。为了开始解开克罗山特尔的作用，使用基于反向片段的研究来定义对克罗山特尔几丁质酶抑制剂功能至关重要的结构元素。由于针对忽视的热带病开发新药物的资源匮乏，发现一种对O. volvulus产生影响的现有药物，为寻找治疗河盲症的新疗法提供了希望。